Associated Genetic Biomarkers
ATRX Deletion is present in 0.08% of AACR GENIE cases, with sarcoma, malignant glioma, breast carcinoma, prostate cancer, and colorectal adenocarcinoma having the greatest prevalence .
ATRX Deletion serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ATRX Deletion as an inclusion criterion, 1 is phase 2 (1 open).
Trials with ATRX Deletion in the inclusion eligibility criteria most commonly target urothelial carcinoma .
Olaparib is the most frequent therapy in trials with ATRX Deletion as an inclusion criteria .
Significance of ATRX Deletion in Diseases
Urothelial Carcinoma +
ATRX is mutated in 6.2% of urothelial carcinoma patients .
ATRX Deletion is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX Deletion and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Olaparib is the most frequent therapy in trials for urothelial carcinoma that contain ATRX Deletion .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.